<DOC>
	<DOC>NCT01493882</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting beta 2-agonist (LABA) and/or montelukast for at least 4 weeks.</brief_summary>
	<brief_title>Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma</brief_title>
	<detailed_description>This is a two-part study; each part of the study (Part 1 and Part 2) will be approximately 34 weeks in duration including a 4-week screening phase, a 24-week placebo-controlled treatment phase and a six-week follow-up phase. In Part 1, patients will be randomly assigned to receive placebo or JNJ-39758979 300 mg once daily through Week 24. In Part 2, patients will be randomly assigned to 1 of 4 treatment groups to receive treatment with placebo, 30 mg, 100 mg, or 300 mg of JNJ-39758979 once daily through Week 24. Safety assessments and evaluations to determine the efficacy of JNJ-39758979 to reduce the signs and symptoms of asthma will be performed both on a daily basis via electronic diary and at study visits.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Has a diagnosis of asthma for at least 6 months before screening. Has been receiving inhaled corticosteroids (≤ 1000 µg fluticasone or its equivalent) alone or in conjunction with longacting Beta 2agonist (salmeterol, formoterol, etc.) and/or montelukast. Have an ACQ score ≥ 1.5 at screening. Must be healthy and medically stable on the basis of physical examination, medical history, vital signs, and 12lead electrocardiogram (ECG) performed at screening Must be postmenopausal or if premenopausal, must use an acceptable method of birth control. Has ever had a lifethreatening asthma attack including respiratory arrest, intubation, or intensive care unit admission due to asthma. Has a history of any other chronic respiratory condition including chronic obstructive pulmonary disease, bronchiolitis, bronchiectasis, allergic bronchopulmonary aspergillosis (mycosis), occupational asthma, sleep apnea or pulmonary hypertension.Has initiated or discontinued allergen immunotherapy within 12 weeks of screening. Has smoked within 3 years of screening or has a history of smoking ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year) or equivalent, or a positive urine cotinine test at Screening. Has any known malignancy or has a history of malignancy with the exceptions of basal cell carcinoma or squamous cell carcinoma. Has chronic or recurrent infectious disease, including, but not limited to: active tuberculosis.Has a clinically significant, acute respiratory infection within 4 weeks of screening. Has had a substance abuse (drug or alcohol) problem within the previous 3 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Uncontrolled Persistent Asthma, Dyspnea, Wheezing</keyword>
</DOC>